Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[11C]-Lu AF88370 PET Study in Healthy Men
NCT05320302Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Mar 2022
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Lu AF88370 in cognitive impairment, Neurodegenerative disorders (NDDs) and psychiatric disorders, sponsored by Lundbeck. Primary endpoints: Whole Brain Total Distribution Volume at Day 1 and VT of [11C]-Lu AF88370 in Regions of Interest at Day 1. Started Mar 2022; status: completed.
02
Drugs
Lu AF88370
03
Conditions
cognitive impairmentNeurodegenerative disorders (NDDs)psychiatric disorders
Beyond the preview
Go deeper on NCT05320302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05320302.